Holen Sie sich die Stockscreener-App
11.44
1.87%
0.21
Vorhandelsmarkt:
11.32
-0.12
-1.05%
Omeros Corporation Aktie (OMER) Neueste Nachrichten
What risks investors should watch in Omeros Corporation stockWeekly Investment Report & Long-Term Safe Investment Plans - mfd.ru
Omeros Achieves Commercial Milestone with First Approved Drug Launch - AD HOC NEWS
Macro Review: What is the long term forecast for Omeros Corporation stockStock Surge & Community Shared Stock Ideas - baoquankhu1.vn
Omeros Corporation's (NASDAQ:OMER) market cap dropped US$60m last week; individual investors who hold 50% were hit as were institutions - Yahoo Finance
Omeros wins FDA nod for transplant therapy - MSN
Omeros Corporation (NASDAQ:OMER) Sees Large Growth in Short Interest - MarketBeat
EV Market: Is Omeros Corporation gaining market shareTrade Entry Report & Daily Profit Focused Stock Screening - baoquankhu1.vn
Omeros higher after first commercial sales of transplant therapy - MSN
Is Omeros Corporation gaining market shareJuly 2025 Gainers & Safe Entry Momentum Stock Tips - mfd.ru
Omeros begins commercial distribution of TA-TMA treatment Yartemlea By Investing.com - Investing.com Australia
Big Money Moves: What is the implied volatility of Air Products and Chemicals IncWeekly Market Outlook & Real-Time Market Sentiment Reports - baoquankhu1.vn
Omeros Shares Rise After Starting Commercial Sales of Stem Cell Complication Drug Yartemlea - marketscreener.com
Omeros (OMER) Rises on First Shipments of Yartemlea - GuruFocus
Omeros wins first commercial sales of Yartemlea (OMER:NASDAQ) - Seeking Alpha
OMER: D. Boral Capital Maintains Buy Rating with $36 Price Targe - GuruFocus
Omeros (NASDAQ:OMER) Given "Buy" Rating at D. Boral Capital - MarketBeat
Omeros stock rises as first commercial YARTEMLEA shipments begin By Investing.com - Investing.com Canada
Omeros stock rises as first commercial YARTEMLEA shipments begin - Investing.com
Omeros Begins Commercial Sales of Stem Cell Complication Drug Yartemlea - marketscreener.com
Omeros (OMER) Begins Commercial Distribution of Yartemlea for TA-TMA - GuruFocus
Omeros announces first commercial sales of Yartemlea - TipRanks
Omeros begins commercial distribution of TA-TMA treatment Yartemlea - Investing.com
Omeros Announces First Commercial Sales of YARTEMLEA® - Yahoo Finance
Omeros Corporation (NASDAQ:OMER) Receives Consensus Rating of "Moderate Buy" from Brokerages - MarketBeat
A Deal With Novo Nordisk Sent This Stock 181% Higher Overnight. Is It a Buy Now? - AOL.com
Omeros (NASDAQ:OMER) Shares Pass Above Two Hundred Day Moving AverageWhat's Next? - MarketBeat
Portfolio Update: Can Omeros Corporation maintain sales growthJuly 2025 Opening Moves & Free Real-Time Market Sentiment Alerts - baoquankhu1.vn
Growth Value: Should you buy the dip on Omeros CorporationQuarterly Growth Report & Fast Gain Stock Tips - baoquankhu1.vn
Omeros Shares Face Headwinds Amid Mixed Signals - AD HOC NEWS
Omeros stock garners high retail attention ahead of FDA verdict for life-saving drug - MSN
Omeros (NASDAQ:OMER) Shares Down 5.8% Following Insider Selling - MarketBeat
Omeros (NASDAQ:OMER) CAO Sells 30,000 Shares - MarketBeat
Omeros (OMER) Price Target Increased by 29.70% to 44.54 - Nasdaq
Omeros VP Borges sells $750k in shares By Investing.com - Investing.com Nigeria
Omeros VP Borges sells $750k in shares - Investing.com
Omeros Corp Sells Immune-System Drug To Novo Nordisk In $2.1B Deal — Retail Shifts Focus To Narsoplimab FDA Call - msn.com
HC Wainwright Has Bearish Outlook for Omeros FY2026 Earnings - MarketBeat
Why did Omeros stock jump 5% in after-hours trading today? - MSN
Omeros (OMER) Price Target Increased by 12.22% to 34.34 - MSN
1.24%
0.19%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):